Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: red_dog who wrote (86040)	3/2/2000 1:21:00 PM
From: red_dog	Respond to of 120523

This is probably already known! Nexell Therapeutics Files SuitAgainst Miltenyi Biotec/AmCell March 2, 2000 08:30 AM IRVINE, Calif.--(BW HealthWire)--March 2, 2000--Nexell Therapeutics Inc. NEXL , one of the world's leading suppliers of therapeutic products based on hematopoietic stem cell technology, announced today that it has filed suit in the U.S. District Court in Delaware against Miltenyi Biotec GmbH of Germany and its related U.S. companies, Miltenyi Biotec, Inc. and AmCell Corporation. The suit charges Miltenyi with patent infringement, breach of contract and deceptive trade practices. Joining Nexell in the suit are Becton, Dickinson and Company and The Johns Hopkins University, both of whom have proprietary rights associated with Nexell's technology. Nexell intends to ask the court for damages and injunctive relief